Filing Flows › Tenaya Therapeutics (TNYA) › Guidance & outlook
Tenaya Therapeutics (TNYA) guidance and outlook
Tenaya Therapeutics' 10-Q filed Nov 4, 2026 makes 19 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 4, 2026
- Early on in our company history, we invested in differentiated capabilities to enable modality-agnostic target identification and validation, anchored in human genetics and the use of human disease models.
- We plan to share additional follow-up data in the fourth quarter of 2026 and to provide an update on our interactions with regulators.
- In March 2026, we entered into a multi-target research collaboration with Alnylam Pharmaceuticals, Inc.
- We expect to present one-year Cohort 2 data and two-year durability data for Cohort 1 from MyPEAK-1 by year end.
- We are also in ongoing discussions with regulatory authorities, with an additional interaction planned to explore late-stage pivotal trial plans for TN-201, and intend to provide an update by year end.
- We expect to present interim data by year end, including one-year data for Cohort 2 and durability data for Cohort 1.
- We plan to provide an update on the feedback received from our discussions by year end.
- We plan to advance TN-301 toward clinical trials in patients in order to generate proof-of-activity data, with HFpEF and DMD being among the most promising potential indications identified to date.
- We are currently conducting enabling toxicology work to support such advancement and plan to initiate at least one company-sponsored Phase 2 clinical trial in the second half of 2027.
- As a result, we cannot reasonably estimate or know the nature, timing or estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.
- The level of our research and development expenses over the next twelve months will be subject to operational decisions
- We will continue to incur legal, accounting, insurance and other expenses in operating our business as a public company, including costs associated with regulatory and compliance activities.
Tenaya Therapeutics' latest quarter
Tenaya Therapeutics, Q3 2026: revenue $1.7M, net loss $18.9M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
Questions
What does Tenaya Therapeutics expect?
Early on in our company history, we invested in differentiated capabilities to enable modality-agnostic target identification and validation, anchored in human genetics and the use of human disease models. We plan to share additional follow-up data in the fourth quarter of 2026 and to provide an update on our interactions with regulators. In March 2026, we entered into a multi-target research collaboration with Alnylam Pharmaceuticals, Inc.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.